Haiyan He

Apr 16, 2024 | medrxiv.org | Haiyan Yang |Haiyan He |Ning Li |Binyang Yu

The authors have declared no competing interest. The author(s) received no specific funding for this work. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data in this study were sourced from public databases, and did not contain any personally identifiable information or personal data.

Sep 15, 2023 | journals.sagepub.com | Haiyan He |Jun Ge |Yuhong Wang |Shaona Yi

IntroductionCisplatin (cis-diaminodichlorplatin (II), CP) is a highly effective chemotherapy drug for various tumor types.1–3 However, the long-term clinical application of CP results in the serious side effects (nephrotoxicity, ototoxicity, neurotoxicity, and emetogenicity. Among these side effects, nephrotoxicity is a main sequela.4 Approximately one third of patients treated with cisplatin have renal dysfunction.

Jul 9, 2023 | mdpi.com | Haiyan He

Abstract:Users of utility tunnel public–private partnership (PPP) projects are productive corporate entities with a specific scope, a limited quantity, and strong bargaining power. They possess the ability and motivation to participate in PPP projects through equity investments. Tunnel PPP projects involving user participation are implemented jointly by consortia comprising construction contractors and users.

Feb 17, 2023 | mdpi.com | Haiyan He |JIng Lu |Wanting Qiang |Jin Liu

Abstract:Interphase fluorescence in situ hybridization (iFISH) has been well established in the preliminary prognostic evaluation of multiple myeloma (MM). However, the chromosomal aberrations in patients with systemic light-chain amyloidosis, notably in patients with coexistent MM, have been rarely investigated. This study aimed to evaluate the effect of iFISH aberrations on the prognosis of systemic light-chain amyloidosis (AL) with and without concurrent MM.